

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2021 September 15; 13(9): 980-1212



### REVIEW

- 980** Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression  
*Fujita M, Suzuki H, Fukai F*
- 995** MicroRNA expression in inflammatory bowel disease-associated colorectal cancer  
*Grillo TG, Quaglio AEV, Beraldo RF, Lima TB, Baima JP, Di Stasi LC, Sasaki LY*
- 1017** Association between intestinal neoplasms and celiac disease: A review  
*Wang M, Yu M, Kong WJ, Cui M, Gao F*
- 1029** Real-time fluorescence image-guided gastrointestinal oncologic surgery: Towards a new era  
*Martínez-López E, Martínez-Pérez A, Navarro-Martínez S, Sebastián-Tomás JC, de'Angelis N, García-Granero E*
- 1043** Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature  
*Guo M, Jin N, Pawlik T, Cloyd JM*

### MINIREVIEWS

- 1062** Review of incomplete macroscopic resections (R2) in rectal cancer: Treatment, prognosis and future perspectives  
*Pérez Lara FJ, Hebrero Jimenez ML, Moya Donoso FJ, Hernández Gonzalez JM, Pitarch Martinez M, Prieto-Puga Arjona T*
- 1073** Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review  
*Shotton R, Lamarca A, Valle J, McNamara MG*
- 1086** Conservative management of malignant gastric outlet obstruction syndrome-evidence based evaluation of endoscopic ultrasound-guided gastroentero-anastomosis  
*Cominardi A, Tamanini G, Brighi N, Fusaroli P, Lisotti A*
- 1099** Overgrowth of *Lactobacillus* in gastric cancer  
*Li ZP, Liu JX, Lu LL, Wang LL, Xu L, Guo ZH, Dong QJ*
- 1109** Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system  
*Herold Z, Szasz AM, Dank M*
- 1121** Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis  
*Hoskins B, Wasuwanich P, Scheimann AO, Karnsakul W*
- 1132** Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy  
*Mattos ÁZ, Debes JD, Boonstra A, Vogel A, Mattos AA*



- 1144 Characterization of metabolic landscape in hepatocellular carcinoma

*Wu J, Xue R, Jiang RT, Meng QH*

- 1157 Effect of oncometabolic surgery on gastric cancer: The remission of hypertension, type 2 diabetes mellitus, and beyond

*Cheng YX, Peng D, Tao W, Zhang W*

## ORIGINAL ARTICLE

### Basic Study

- 1164 Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway

*Li N, Yang F, Liu DY, Guo JT, Ge N, Sun SY*

### Retrospective Study

- 1184 Prognostic value of modified Lauren classification in gastric cancer

*Ning FL, Zhang NN, Wang J, Jin YF, Quan HG, Pei JP, Zhao Y, Zeng XT, Abe M, Zhang CD*

## META-ANALYSIS

- 1196 Neoadjuvant chemotherapy without radiation as a potential alternative treatment for locally advanced rectal cancer: A meta-analysis

*Wu P, Xu HM, Zhu Z*

## LETTER TO THE EDITOR

- 1210 Use of liquid biopsies in gastrointestinal cancers

*Khachfe HH*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Rossana Berardi, MD, PhD, Director, Full Professor, Medical Oncology, Università Politecnica delle Marche, Ancona 60126, Italy. [r.berardi@staff.univpm.it](mailto:r.berardi@staff.univpm.it)

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

**INDEXING/ABSTRACTING**

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Ying-Yi Yuan*, Production Department Director: *Xiang Li*, Editorial Office Director: *Ya-Juan Ma*.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Rosa M Jimenez Rodriguez, Pashtoon Kasi, Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

September 15, 2021

**COPYRIGHT**

© 2021 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>





Basic Study

## Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway

Na Li, Fan Yang, Dong-Yan Liu, Jin-Tao Guo, Nan Ge, Si-Yu Sun

**ORCID number:** Na Li 0000-0002-9841-2200; Fan Yang 0000-0002-5032-6450; Dong-Yan Liu 0000-0002-3902-9316; Jin-Tao Guo 0000-0001-5722-6359; Nan Ge 0000-0002-5764-7054; Si-Yu Sun 0000-0002-7308-0473.

**Author contributions:** Li N and Sun SY conceived and designed the study; Li N performed the assays, analyzed and interpreted the data, and drafted the article; Yang F and Liu DY gave guidance and advice; Ge N and Guo JT revised the article for important intellectual content; all authors performed the final approval of the article.

**Supported by** National Natural Science Foundation of China, No. 817706555; Special Project from the Central Government of Liaoning Province, No. 2018107003; Liaoning Province Medical Science and Technology Achievements Transformation Foundation, No. 2018225120; China Postdoctoral Science Foundation, No. 2020M670101ZX; Doctoral Scientific Research Foundation of Liaoning Province, No. 2019-BS-276; Science and Technology Program of Shenyang, No. 19-112-4-103; Youth Support Foundation of China Medical University, No. QGZ2018058; Scientific Fund of Shengjing Hospital, No. 201801;

**Na Li**, Department of Hospice Care, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China

**Fan Yang, Jin-Tao Guo, Nan Ge, Si-Yu Sun**, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China

**Dong-Yan Liu**, Medical Research Center, Shengjing Hospital of China Medical University, Benxi 111700, Liaoning Province, China

**Corresponding author:** Si-Yu Sun, MD, PhD, Chief Doctor, Doctor, Professor, Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. [sun-siyu@163.com](mailto:sun-siyu@163.com)

### Abstract

#### BACKGROUND

Pancreatic cancer is a highly malignant tumor of the gastrointestinal system whose emerging resistance to chemotherapy has necessitated the development of novel antitumor treatments. Scoparone, a traditional Chinese medicine monomer with a wide range of pharmacological properties, has attracted considerable attention for its antitumor activity.

#### AIM

To explore the potential antitumor effect of scoparone on pancreatic cancer and the possible molecular mechanism of action.

#### METHODS

The target genes of scoparone were determined using both the bioinformatics and multiplatform analyses. The effect of scoparone on pancreatic cancer cell proliferation, migration, invasion, cell cycle, and apoptosis was detected *in vitro*. The expression of hub genes was tested using quantitative reverse transcription polymerase chain reaction (qRT-PCR), and the molecular mechanism was analyzed using Western blot. The *in vivo* effect of scoparone on pancreatic cancer cell proliferation was detected using a xenograft tumor model in nude mice as well as immunohistochemistry.

#### RESULTS

The hub genes involved in the suppression of pancreatic cancer by scoparone were obtained by network bioinformatics analyses using publicly available

and 345 Talent Project of Shengjing Hospital, No. 52-30C.

#### Institutional review board

**statement:** The study was reviewed and approved by the Ethics Review Committee and Ethics Committee of Shengjing Hospital of China Medical University (No. 2020PS766K).

#### Institutional animal care and use

**committee statement:** All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Specialty type:** Oncology

**Country/Territory of origin:** China

#### Peer-review report's scientific quality classification

Grade A (Excellent): 0  
Grade B (Very good): B, B  
Grade C (Good): 0  
Grade D (Fair): 0

databases and platforms, including SwissTargetPrediction, STITCH, GeneCards, CTD, STRING, WebGestalt, Cytoscape, and Gepia; *AKT1* was confirmed using qRT-PCR to be the hub gene. Cell Counting Kit-8 assay revealed that the viability of Capan-2 and SW1990 cells was significantly reduced by scoparone treatment exhibiting IC<sub>50</sub> values of 225.2  $\mu$ mol/L and 209.1  $\mu$ mol/L, respectively. Wound healing and transwell assays showed that scoparone inhibited the migration and invasion of pancreatic cancer cells. Additionally, flow cytometry confirmed that scoparone caused cell cycle arrest and induced apoptosis. Scoparone also increased the expression levels of Bax and cleaved caspase-3, decreased the levels of MMP9 and Bcl-2, and suppressed the phosphorylation of Akt without affecting total PI3K and Akt. Moreover, compared with the control group, xenograft tumors, in the 200  $\mu$ mol/L scoparone treatment group, were smaller in volume and lighter in weight, and the percentages of Ki65- and PCNA-positive cells were decreased.

## CONCLUSION

Our findings indicate that scoparone inhibits pancreatic cancer cell proliferation *in vitro* and *in vivo*, inhibits migration and invasion, and induces cycle arrest and apoptosis *in vitro* through the PI3K/Akt signaling pathway.

**Key Words:** Pancreatic cancer; Scoparone; Akt1; PI3K/Akt signaling pathway; Bioinformatics analysis; Xenograft tumor

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** To explore the potential antitumor effect of scoparone on pancreatic cancer and the possible molecular mechanism, target genes of scoparone were determined using the bioinformatics and multiplatform analyses. The effect of scoparone on pancreatic cancer cell proliferation, migration, invasion, cell cycle, and apoptosis was detected. The expression of hub genes was detected using quantitative reverse transcription polymerase chain reaction, and Western blot was used to analyze the molecular mechanism. Xenograft tumor model and immunohistochemistry were used to detect cell proliferation *in vivo*. Our findings indicated that scoparone inhibits pancreatic cancer cell proliferation, migration, and invasion, and induced cell cycle arrest and apoptosis through the PI3K/Akt signaling pathway.

**Citation:** Li N, Yang F, Liu DY, Guo JT, Ge N, Sun SY. Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway. *World J Gastrointest Oncol* 2021; 13(9): 1164-1183

**URL:** <https://www.wjgnet.com/1948-5204/full/v13/i9/1164.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v13.i9.1164>

## INTRODUCTION

Pancreatic cancer is a lethal malignancy with occult onset, difficult early diagnosis, rapid progression, poor therapeutic response, short median survival time, and poor prognosis[1,2]. According to the National Cancer Center of China, the incidence rate of pancreatic cancer is 7/100000, accounting for 2.42% of the cases of malignant tumors in China, and its 5-year survival rate is only 7.2%, which is the lowest survival rate among all malignant tumors[3,4]. Pancreatic cancer is the seventh leading cause of death worldwide[5], with an increasing trend. It is estimated that pancreatic cancer will become the second leading cause of malignant tumor-related deaths by 2030[6]. At present, surgical resection is the primary treatment method for pancreatic cancer; however, only 15%-20% of patients are eligible for surgical resection because of late diagnosis[7]. In recent years, with the development of endoscopic ultrasonography and pathology, early diagnosis of pancreatic cancer has been improved[8-10]; however, there are still only few cases that can be surgically removed. Moreover, pancreatic cancer has a strong tendency to metastasize and a high recurrence rate following surgery. Although gemcitabine, 5-fluorouracil, oxaliplatin, and other chemotherapeutic agents can effectively improve the prognosis of patients with

Grade E (Poor): 0

**Received:** March 4, 2021**Peer-review started:** March 4, 2021**First decision:** April 6, 2021**Revised:** April 9, 2021**Accepted:** July 5, 2021**Article in press:** July 5, 2021**Published online:** September 15, 2021**P-Reviewer:** Oberhardt V, Trivedi P**S-Editor:** Gao CC**L-Editor:** Wang TQ**P-Editor:** Ma YJ

pancreatic cancer, the emergence of drug resistance has lowered the efficacy of these treatments[11]. Meanwhile, the toxicity, negative side effects, and associated costs of chemotherapy remain a challenge. Therefore, the development of novel anti-pancreatic cancer drugs is essential.

Scoparone, also known as 6,7-dimethoxycoumarin, belongs to the coumarin class of natural organic compounds. It is primarily extracted from the dry aerial part of *Artemisia capillaris* Thunb., which is widely used in the prevention and treatment of neonatal jaundice in Asia. Scoparone also has anticoagulant, anti-inflammatory, antifibrosis, and antioxidation activities[12-15], and can act as a vasodilator, reduce blood lipid levels, and exert an antiatherosclerosis effect on the cardiovascular system [16-18]. Jang *et al*[19] found that scoparone may suppress the expression of chemokines (interleukin 8 and monocyte chemoattractant protein-1) by inhibiting the nuclear factor-kappa B signaling pathway in leukemia cells activated by phorbol 12-myristate 13-acetate. In another study, scoparone could reduce the viability and migration of laryngeal cancer cells in a dose-dependent manner by inducing apoptosis without affecting the activity of ERK1/2 and Akt kinase[20]. Scoparone may also inhibit the proliferation of prostate cancer cells by directly interfering with the transcription of signal transducer and activator of transcription 3[21]. In our study, we evaluated the antitumor activity of scoparone on pancreatic cancer cells and investigated the molecular mechanism of action, providing evidence of a potential drug or adjuvant for pancreatic cancer treatment.

## MATERIALS AND METHODS

### Bioinformatics analysis

**Prediction of drug targets:** The following two databases were used to predict targets of scoparone activity: SwissTargetPrediction (<http://www.swisstargetprediction.ch/>), a database for predicting drug targets based on the similarity of two- or three-dimensional structures with known compounds[22]; and STITCH (<http://stitch.embl.de/>, Version:5.0), a platform for searching known and predicted interactions between compounds and proteins, containing 9643763 proteins from 2031 species[23].

**Prediction of pancreatic cancer targets:** The following two databases were used to predict pancreatic cancer-related targets: GeneCards (<https://www.genecards.org>, Version:5.0), a searchable comprehensive database that integrates data from over 150 sources[24]; and Comparative Taxonomic Database (CTD, <http://ctdbase.org>, updated 10/28/2020), which provides information on interactions or relationships between compounds and genes, compounds and proteins, compounds and diseases, or genes and diseases[25]. Targets with a score greater than the median were screened out, and the duplicates were obtained as pancreatic cancer-related targets. In addition, the overlaps of drug and disease targets were the effective targets of scoparone to treat pancreatic cancer.

**Enrichment analysis of potential targets:** WebGestalt (<http://www.webgestalt.org>, updated 01/14/2019) is an online website focusing on functional enrichment analysis [26]. Biological processes, cellular composition, and molecular function were selected for Gene Ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG)[27] was selected for pathway analysis for the predicted pancreatic cancer-related targets of scoparone.

**Protein-protein interaction network:** STRING (<https://string-db.org/cgi/input.pl>, Version 11.0) is an online database for predicting protein-protein interactions (PPIs) [28]. The predicted targets were uploaded into the STRING database to obtain the PPI network, which was then imported into Cytoscape 3.7.2, an open software platform for constructing data analysis, integration, and visualization networks[29]. The software plugins Cytohubba and Network Analyzer[30,31] were used to analyze the network characteristics, in which the degree of the nodes represents the importance of the proteins in the network. The higher the degree value, the darker the node color.

**Expression patterns of candidate hub genes:** Gepia (<http://gepia.cancer-pku.cn/>) is a database that can be used for differential expression analyses between tumor and normal tissues as well as survival and correlation analyses[32]. The expression patterns of candidate hub genes identified by pathway and PPI network analyses were evaluated using Gepia.



### Cell experiments

**Cell culture:** Pancreatic cancer cell lines Capan-2 and SW1990 were respectively purchased from American Type Culture Collection (ATCC, Manassas, VA, United States) and the cell resource center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). Capan-2 cells were cultivated in RPMI-1640 medium (Biological Industries, Beit HaEmek, Israel) and SW1990 cells in L15 medium (Biological Industries) mixed with 10% fetal bovine serum (FBS, Biological Industries) in a 5% CO<sub>2</sub> incubator at 37 °C.

**Cell viability assay:** Capan-2 and SW1990 cells were seeded onto 96-well plates at a density of 4000 cells/well. After 12 h, the medium was replaced with different scoparone (Sigma-Aldrich, St. Louis, MO, United States) concentrations (0, 0.5, 1, 5, 10, 50, 80, 100, 200, 300, 400, 600, and 800 µmol/L) for 48 h. Cell viability was measured with the CCK-8 assay kit (ApexBio Technology, Houston, TX, United States) according to the instructions. Next, the optical density (OD) value at 450 nm was measured, and the IC<sub>50</sub> value was calculated. Cells were then inoculated again with 100, 200, and 400 µmol/L scoparone (1/2 IC<sub>50</sub>, IC<sub>50</sub>, and 2 IC<sub>50</sub>) for 24, 48, and 72 h, and the OD value was measured as compared to the control group (0 µmol/L scoparone with the same amount of DMSO solution of 400 µmol/L scoparone).

**Wound healing assay:** Capan-2 and SW1990 cells were pretreated with 0 (Con), 100, 200, and 400 µmol/L scoparone for 24 h. A vertical wound was drawn in the cells with a 200-µL sterile pipette tip. After washing with phosphate buffer saline (PBS) (Biological Industries), serum-free culture medium was added, and images of the wound were taken at 0, 24, 48, and 72 h using an Eclipse microscope (Nikon Corporation, Tokyo, Japan).

**Transwell assay:** Capan-2 and SW1990 cells were pretreated with 0, 100, 200, and 400 µmol/L scoparone for 24 h, following which the cells were resuspended in serum-free medium. A 200-µL aliquot of cell suspension ( $2.5 \times 10^5$  cells/mL) was added to the upper layer of the cell culture chamber, while 600-µL medium containing 10% FBS was added to the lower level and then incubated in a 5% CO<sub>2</sub> incubator at 37 °C for 16-24 h. The membrane of the upper level was fixed with 4% paraformaldehyde for 2 min, permeated with 100% methanol for 20 min, and then stained with 0.2% crystal violet at 25 °C for 15 min. Under an Eclipse microscope (Nikon Corporation), five fields (200 × magnification) were randomly observed and imaged.

The cell invasion assay was conducted by adding 100 µL of Matrigel (Corning Inc., New York, NY, United States) diluted at a 1:8 ratio in a serum-free medium to the upper level, followed by incubation overnight at 37 °C. The other steps were performed as described in the migration assay above.

**Apoptosis by flow cytometry:** Following the instructions, apoptosis was measured using the PE Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, United States) by flow cytometry. Capan-2 and SW1990 cells were pretreated with 0, 100, 200, and 400 µmol/L scoparone for 24 h. Cells were rinsed twice with cold PBS after digestion with trypsin without EDTA, followed by resuspension and dilution to  $1 \times 10^6$  cells/mL with 1 × Annexin V Binding Buffer; 5 µL of PE Annexin V and 5 µL of 7-AAD reagent were added and then incubated in dark place for 15 min. The FACSCalibur flow cytometer (BD Biosciences) was used to measure the apoptosis rate.

**Cell cycle by flow cytometry:** Following the instructions, cell cycle was measured using PI/RNase Staining Buffer (BD Biosciences) by flow cytometry. Capan-2 and SW1990 cells were pretreated with 0, 100, 200, and 400 µmol/L scoparone for 24 h. Cells were resuspended with cold PBS after digestion and fixed with 70% ethanol overnight at -20 °C and then 500 µL of PI/RNase staining buffer was added to each flow tube and stained in dark place for 15 min. The FACSCalibur flow cytometer (BD Biosciences) was used to measure cell cycle.

**Quantitative reverse transcription polymerase chain reaction:** TRIzol reagent (Invitro-gen, Carlsbad, CA, United States) was used to extract the total RNA, and then the PrimeScript RT reagent kit with gDNA Eraser (Takara Bio, Inc., Beijing, China) was used to reverse transcribe the RNA into cDNA. Using ACTB as an internal reference, real-time polymerase chain reaction (PCR) for *AKT1* and *MAPK8* was performed using TB Green Premix ExTaq II (Takara Bio) with a LightCycler480 II PCR system (Roche, Basel, Switzerland). The relative expression of mRNA was analyzed using 2<sup>-ΔΔC<sub>t</sub></sup> method[33]. The forward primer sequence of *AKT1* was 5'-TGACCATGAAC-GAGTTTGAGTA-3', and the reverse primer was 5'-GAGGATCTTCATGGCGTAGT

AG-3', while the forward primer of *MAPK8* was 5'-ACACCACAGAAATCCCTAGAAG-3', and the reverse primer was 5'-GAATTCGATGATCAACTCACGG-3'.

**Western blot analysis:** Capan-2 and SW1990 cells were pretreated with 0, 100, 200, and 400  $\mu\text{mol/L}$  scoparone for 24 h. RIPA lysis buffer (Beyotime Biotech, Jiangsu, China) was used to lyse the cells and then proteins were separated and transferred to polyvinylidene fluoride (PVDF) membranes (GE Healthcare, Chicago, IL, United States). After blocking with 5% skimmed milk or 5% bovine serum albumin (Beyotime) for 2 h, the membranes were incubated with primary antibodies overnight at 4 °C and then incubated with secondary antibodies at room temperature for 2 h. Finally, an ECL Western blotting substrate (Tanon Science & Technology Co., Ltd., Shanghai, China) was used to visualize the bands with the Amersham imager 680 chemiluminescence imaging system (Amersham imager 680; GE Healthcare, United States). GAPDH (1:10000; Proteintech Group, Wuhan, China) served as a control for normalization, and primary antibodies against the following antigens were employed: PI3K (1:1000; Cell Signaling Technology, Inc., Danvers, MA, United States), Akt (1:2000; Proteintech Group), p-Akt (1:2000; Cell Signaling Technology), MMP9 (1:1000; Proteintech Group), Bcl-2 (1:2000; Proteintech Group), Bax (1:10000; Proteintech Group), and cleaved caspase-3 (1:1000; Cell Signaling Technology).

### Animal experiments

**Xenograft tumor model in nude mice:** The animal experiment was approved by the Animal Ethics Committee of the Institute (Ethical code number: 2020PS766K). Twelve four-week-old BALB/C nude mice were purchased from Beijing Huafukang Bioscience (Beijing, China) and were acclimatized to laboratory conditions (23 °C, 12 h/12 h light/dark, 50% humidity, *ad libitum* access to food and water) for 2 wk prior to experimentation following the regulations of the guidelines of the Animal Care and Ethics Committee of Shengjing Hospital of China Medical University (Shenyang, Liaoning, China). Nude mice received subcutaneous injections of 100- $\mu\text{L}$  Capan-2 cells ( $2 \times 10^6$ ). Tumor length (L) and width (W) and mouse weight were measured every second day. Tumor volume was calculated using the following formula: Tumor volume (V) =  $(L \times W^2)/2$ . When V reached approximately 100  $\text{mm}^3$  after 7-10 d, 12 nude mice were randomly and equally divided into either a control group or an experimental group. The control group was intraperitoneally injected with 50  $\mu\text{L}$  of normal saline solution, while the experimental group was injected with 50  $\mu\text{L}$  of 200  $\mu\text{mol/L}$  scoparone every 2 d for 3 wk. The nude mice were euthanized by sodium pentobarbital overdose (150 mg/kg) by intraperitoneal injection, following which the tumors were excised, photographed, measured, and weighed.

**Immunohistochemistry:** Tumor samples were fixed with 4% paraformaldehyde for 48 h and then dehydrated and paraffin-embedded. Tissue sections (3  $\mu\text{m}$ ) were deparaffinized, rehydrated, and antigen-repaired. After blocking, sections were incubated with primary antibodies anti-Ki67 (1:200; Abcam, Cambridge, United Kingdom) and anti-PCNA (1:500; Proteintech Group) for 12-16 h at 4 °C, then incubated with the secondary antibody goat anti-rabbit immunoglobulin G at room temperature for 30 min. Sections were stained with 3,3'-diaminobenzidine (DAB), counter-stained with hematoxylin, dehydrated with gradient ethanol, cleared with xylene, sealed with neutral gum, observed, and photographed under an Eclipse microscope (Nikon Corporation).

### Statistical analysis

Data are represented as the mean  $\pm$  SD, and *t*-test (between two groups) or one-way ANOVA (multiple groups) was used for statistical analyses with IBM SPSS Statistics v. 25.0 software (IBM Corp., Armonk, NY, United States) and GraphPad Prism 8.0 software (GraphPad Software, La Jolla, CA, United States). A *P* value < 0.05 indicated statistical significance. All experiments were repeated at least three times.

## RESULTS

### Potential targets of scoparone in pancreatic cancer

One hundred and thirteen predicted scoparone targets were identified by searching the SwissTargetPrediction database and STITCH platform. Meanwhile, 11691 and 27717 pancreatic cancer-related targets were identified by searching the GeneCards

and CTD databases, respectively. Among them, 5806 disease targets with scores > the median 2.1 and 13855 targets with scores > the median 10.98 were screened out; moreover, 4719 duplicates were obtained as pancreatic cancer-related targets. Finally, a total of 83 therapeutic pancreatic cancer targets of scoparone were obtained by overlapping disease and drug targets (Figure 1B).

### Enrichment analysis

Eighty-three predicted pancreatic cancer targets of scoparone were imported into WebGastalt for functional enrichment analysis, including GO analysis (Figure 1C) and KEGG analysis (Figure 1D). The top ten enrichment pathways among the tumor-related signaling pathways in which scoparone might be involved were mapped into a volcanic plot. These included the MAPK signaling pathway, the PI3K/Akt signaling pathway, pathways in cancer, and the tumor necrosis factor (TNF) signaling pathway. These four pathways involved 34 targets, among which two targets, IKBKB and Akt1, participated in the four pathways, whereas nine targets, including FLT4, EGFR, IGF1R, MET, PDGFRb, ERBB2, MAPK8, MAPK10, and RPS6KA5, were involved in three of the four pathways (Figure 1E).

### Analysis of PPI network

The PPI network between 83 scoparone and pancreatic cancer targets was identified using the STRING database, in which eight proteins, including CA1, CA4, CA12, GPR35, KDM4C, MAOA, METAP1, and PIM3, were not involved in the interaction network (Figure 2A). Then, the PPI network was visualized by Cytoscape (Figure 2B). The top five targets were Akt1, SRC, HSP90AA1, MAPK8, EGFR, and PTGS2 (EGFR and PTGS2 were both in the fifth place), which overlapped with targets related to the signaling pathways. *AKT1* was the most likely candidate hub gene to be influenced by scoparone in pancreatic cancer, followed by *MAPK8* and *EGFR*.

### Analysis of expression patterns of candidate hub genes

The Gepia database was used to analyze *AKT1*, *MAPK8*, and *EGFR* expression differences (Figure 2C). *AKT1* and *MAPK8* expression differed significantly between pancreatic cancer and normal pancreatic tissues, in which the expression of *AKT1* was significantly higher than that of *MAPK8*. From this analysis, it can be inferred that scoparone may suppress pancreatic cancer by inhibiting the expression of *AKT1*, followed by that of *MAPK8*.

### Scoparone inhibits proliferation of pancreatic cancer cells

The viability of Capan-2 and SW1990 cells was significantly reduced by scoparone treatment in a dose-dependent manner, exhibiting  $IC_{50}$  values of 225.2  $\mu\text{mol/L}$  and 209.1  $\mu\text{mol/L}$ , respectively (Figure 2D and E). Compared with the control group, scoparone inhibited the proliferation of Capan-2 and SW1990 cells in a dose- and time-dependent manner ( $P < 0.0001$ , Figure 2F and G).

### Scoparone inhibits migration and invasion of pancreatic cancer cells

The results of the wound healing assay demonstrated that the migration ability of Capan-2 and SW1990 cells was reduced in a dose-dependent manner compared with the control group after treatment with scoparone ( $P < 0.05$ ; Figure 3A-D). Further, the results of the transwell assay revealed that the migration and invasion abilities of Capan-2 and SW1990 cells were significantly decreased by scoparone treatment compared with the control group ( $P < 0.05$ ; Figure 3E-H).

### Scoparone causes cell cycle arrest and induces apoptosis


Flow cytometry results indicated that the abundance of Capan-2 and SW1990 cells increased in the G0/G1 phase compared with the control group, whereas that decreased in the S phase, and no noticeable change was observed in the abundance of cells in the G2/M phase (Figure 4A-C). Meanwhile, scoparone treatment could induce the apoptosis of Capan-2 and SW1990 cells, as the 100, 200, and 400  $\mu\text{mol/L}$  scoparone groups had significantly higher apoptosis rates than the control group (Figure 4D-F). Flow cytometry verified that scoparone could inhibit cell proliferation by causing cell cycle arrest in the G0/G1 phase and inducing apoptosis.

### Scoparone inhibits the PI3K/Akt signaling pathway in pancreatic cancer cells


To further explore the antitumor molecular mechanism of scoparone, quantitative reverse transcription PCR (qRT-PCR) and Western blot were performed. First, qRT-PCR confirmed that *AKT1* expression was decreased in the 200  $\mu\text{mol/L}$  scoparone






**A**




**B**



**C**






**Figure 1** Target genes of scoparone in pancreatic cancer obtained by network bioinformatics analyses. A: The two-dimensional structure of scoparone; B: A total of 83 overlapping therapeutic pancreatic cancer targets of scoparone; C: GO analysis of 83 predicted pancreatic cancer targets of scoparone through the WebGastalt database; D: KEGG analysis of 83 predicted pancreatic cancer targets of scoparone through the WebGastalt database; E: Overlapping targets in four enriched pathways identified by KEGG analysis.

group compared with the control group, whereas *MAPK8* expression was increased (Figure 5E and F). The PI3K/Akt signaling pathway, the key pathway most likely related to Akt1 expression and the antitumor effect, was analyzed using Western blot. Scoparone treatment did not decrease the total expression of PI3K and Akt, but it inhibited p-Akt expression, which may have led to significantly decreased MMP9 and Bcl-2 expression and increased Bax and cleaved caspase-3 expression (Figure 5G-J). These results suggested that scoparone could reduce the migration and invasion of pancreatic cancer cells and induce apoptosis through PI3K/Akt signaling pathway.


#### Scoparone inhibits xenograft tumor growth *in vivo*

To investigate the suppression of pancreatic cancer cell proliferation *in vivo*, xenograft tumors were derived from Capan-2 cells in nude mice. Xenograft tumors in the 200  $\mu\text{mol/L}$  scoparone group were smaller in volume and lighter in weight than those in the control group (Figure 5G-I). Immunohistochemistry (IHC) revealed that the percentages of Ki67- and PCNA-positive cells in the 200  $\mu\text{mol/L}$  scoparone group were significantly decreased compared with those of the control group (Figure 5J-L). It is suggested that scoparone could suppress the growth of pancreatic cancer *in vivo*.


**A**



**B**








**Figure 2 Protein-protein interaction network of the 83 predicted targets and scoparone inhibits proliferation.** A: Protein-protein interaction (PPI) network of the 83 predicted targets through STRING; B: Visualized PPI network of the 83 predicted targets through Cytoscape 3.7.2. Darker nodes indicate higher degree value; C: Expression patterns of the following candidate hub genes: *AKT1*, *MAPK8*, and *EGFR*; the red represents the tumor group and the gray represents the normal group; D and E:  $IC_{50}$  values of scoparone for Capan-2 and SW1990 cells shown by CCK-8 assay; F and G: Scoparone inhibits the proliferation of Capan-2 and SW1990 cells. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ , <sup>c</sup> $P < 0.001$ , <sup>d</sup> $P < 0.0001$  vs the control group.

## DISCUSSION


Pancreatic cancer, known as “the king of cancers”, has the lowest survival rate among all malignant tumors. At present, chemotherapy can improve the survival of patients with pancreatic cancer; however, drug resistance, toxicity, adverse effects, and the high cost of chemotherapy limit its effectiveness. Therefore, exploring new therapeutic targets and drugs remains an important strategy for the treatment of pancreatic cancer. In recent years, natural products have attracted considerable attention due to their reliable efficacy and relatively few side effects[34]. Scoparone, a phenylpropanoid monomer used in traditional Chinese medicine, has a wide range of pharmacological properties, and its antitumor activity has been confirmed in leukemia, laryngeal cancer, and prostate cancer. However, to date, no study has demonstrated its effect on other tumors or determined its underlying molecular mechanism.

The inhibitory effect of scoparone *in vitro* and *in vivo* on pancreatic cancer and its associated molecular mechanism were investigated in this study. The current study results concur with those of previous studies in terms of inhibiting cell proliferation; scoparone inhibited pancreatic cell proliferation by causing cell cycle arrest in the G0/G1 phase and inducing apoptosis. Meanwhile, Western blot analysis demonstrated that the expression of the anti-apoptotic protein Bcl-2 was reduced, whereas that of the proapoptotic proteins, Bax, and cleaved caspase-3 was increased after scoparone treatment. Downregulation of anti-apoptotic protein and upregulation of pro-apoptotic protein can lead to increased apoptosis. In addition to the wound healing and transwell assay results, the expression of MMP9, which is associated with cancer cell invasion and metastasis, was decreased after scoparone treatment, further indicating that scoparone inhibited the migration and invasion of pancreatic cancer cells. Finally, xenograft tumor and IHC results confirmed the inhibitory effect of scoparone on pancreatic cancer cell proliferation *in vivo*, which is an advantage over previous studies.

In the present study, the hub genes involved in the suppression of pancreatic cancer by scoparone were obtained by network bioinformatics analyses using public databases and platforms, including SwissTargetPrediction, STITCH, GeneCards, CTD, STRING, WebGestalt, Cytoscape, and Gepia. Ultimately, *AKT1* was confirmed, using










**Figure 3 Scoparone inhibits pancreatic cancer cell migration and invasion.** A-D: Scoparone inhibits migration of Capan-2 (A and C) and SW1990 (B and D) cells by wound healing assay; E-H: Scoparone inhibits migration and invasion of Capan-2 (E and F) and SW1990 (G and H) cells by transwell assay. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ , <sup>c</sup> $P < 0.001$ , <sup>d</sup> $P < 0.0001$  vs the control group.

qRT-PCR, to be the hub gene involved in pancreatic cancer suppression by scoparone. Serine/threonine kinase Akt, also known as protein kinase B, consists of isomers Akt1/PKB  $\alpha$ , Akt2/PKB  $\beta$ , and Akt3/PKB  $\gamma$ , which are the products of three different genes, rather than alternative splicing of one gene[35]. Although the genes encoding these isomers are different, their amino acid homology reaches 80% [36,37], of which Akt1 is the most important and characteristic subtype that participates in the occurrence and development of various tumors through numerous signaling pathways. Among these, the PI3K/Akt signaling pathway is one of the most frequently activated pathways in tumors. Increasing studies have confirmed that the PI3K/Akt signaling pathway is involved in tumor cell survival, proliferation, metabolism, growth, metastasis, and drug resistance[38,39]. In pancreatic cancer, the PI3K/Akt signaling pathway also functions as an antitumor drug target. Xu *et al* [40] found that canagliflozin exerted antitumor effects by inhibiting glycolysis through the PI3K/Akt/mTOR signaling pathway, which was improved when combined with gemcitabine, revealing the potential of this pathway in the clinical treatment of pancreatic cancer. However, previous studies investigating the antitumor mechanism of scoparone were insufficient and ambiguous. The findings of this study showed that scoparone inhibits proliferation, metastasis, and invasion of pancreatic cancer cells by










**Figure 4 Scoparone causes cell cycle arrest and induces apoptosis.** A-C: Scoparone causes G0/G1 phase arrest of Capan-2 and SW1990 cells by flow cytometry. The abundance of Capan-2 (B) and SW1990 (C) cells increased in the G0/G1 phase and decreased in the S phase compared with the control group; D-F: Scoparone induces the apoptosis of Capan-2 (E) and SW1990 (F) cells. The 100, 200, and 400  $\mu\text{mol/L}$  scoparone groups had significantly higher apoptosis rates than the control group; G-J: Protein levels of MMP9, Bcl-2, Bax, and cleaved caspase-3 compared with those of the internal control GAPDH in Capan-2 (G and H) and SW1990 (I and J) cells. Decreased MMP9 and Bcl-2 expression and increased Bax and cleaved caspase-3 expression were observed. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ , <sup>c</sup> $P < 0.001$ , <sup>d</sup> $P < 0.0001$  vs the control group.


cell cycle arrest and apoptosis through the PI3K/Akt signaling pathway.

## CONCLUSION

In summary, the present study confirmed that scoparone plays an antitumor role in pancreatic cancer through the PI3K/Akt signaling pathway. However, there are some limitations to this study. First, the targets predicted using the publicly available databases may not be integrated. Second, other tumor-related signaling pathways, such as MAPK and TNF, may also participate in the antitumor effect of scoparone. Finally, pharmacokinetic analyses of scoparone were not conducted in the present study, thus the clinical applications warrant further investigations. Nevertheless, the results of the present study suggest that scoparone is likely to be an effective drug or







**Figure 5 Scoparone inhibits the PI3K/Akt signaling pathway.** A-D: Scoparone inhibits the PI3K/Akt signaling pathway in Capan-2 (A and B) and SW1990 (C and D) cells. Scoparone treatment did not decrease the total expression of PI3K and Akt, but decreased p-Akt expression; E and F: Scoparone decreases the expression of *AKT1* (E) and increases the expression of *MAPK8* (F) as shown by quantitative reverse transcription polymerase chain reaction; G: Images of nude mice and xenograft tumors after treatment with 200  $\mu\text{mol/L}$  scoparone compared with the control group; H: Tumor volume at different time points after treatment with 200  $\mu\text{mol/L}$  scoparone compared with the control group; I: Tumor weight after treatment with 200  $\mu\text{mol/L}$  scoparone compared with the control group; J: Immunohistochemistry (IHC) was performed on xenograft tumors to evaluate PCNA and Ki67 expression. Shown are representative images; K and L: The number of PCNA or Ki67 positive cells were counted from PCNA IHC (K) and Ki67 IHC (L), and decreased PCNA and Ki67 were observed after treatment with scoparone. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ , <sup>c</sup> $P < 0.001$ , <sup>d</sup> $P < 0.0001$  vs the control group.

adjuvant for pancreatic cancer treatment and provide directions for exploring new antitumor drugs.

## ARTICLE HIGHLIGHTS

### Research background

Pancreatic cancer is a highly malignant tumor whose treatment is not effective, so it is necessary to develop new anti-pancreatic cancer treatments. Scoparone has attracted considerable attention for its antitumor activity.

### Research motivation

To explore a new method to develop anti-tumor drugs.

### Research objectives

To explore the potential antitumor effect of scoparone on pancreatic cancer and the possible molecular mechanism of action.

### Research methods

The target genes of scoparone were determined using the bioinformatics analyses. The effect of scoparone on pancreatic cancer cell proliferation, migration, invasion, cell cycle, and apoptosis was detected *in vitro*. The expression of hub genes was tested using quantitative reverse transcription polymerase chain reaction, and the molecular mechanism was analyzed using Western blot. The *in vivo* effect of scoparone on pancreatic cancer cell proliferation was detected using a Xenograft tumor model in nude mice and immunohistochemistry.

### Research results

Our findings indicated that scoparone inhibited pancreatic cancer cell proliferation *in vitro* and *in vivo*, inhibited migration and invasion, and induced cycle arrest and apoptosis *in vitro* through the PI3K/Akt signaling pathway.

### Research conclusions

Scoparone inhibits pancreatic cancer cell proliferation, migration, and invasion, and induces cycle arrest and apoptosis through the PI3K/Akt signaling pathway.

### Research perspectives

Pharmacokinetic analyses of scoparone were not conducted in the present study, thus the clinical applications warrant further investigations.

## REFERENCES

- 1 **Săftoiu A**, Bhutani MS, Itoi T, Arcidiacono PG, Bories E, Cazacu IM, Constantin A, Coronel E, Dietrich CF, Duda DG, Garcia JI, Hocke M, Ignee A, Jenssen C, Jinga M, Khor C, Oppong KW, Pereira S, Petrone MC, Santo E, Seicean A, Seo DW, Siyu S, Vilmann P, Waxman I, Yeaton P. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol. *Endosc Ultrasound* 2019; **8**: 235-240 [PMID: [31249159](#) DOI: [10.4103/eus.eus\\_16\\_19](#)]
- 2 **Bhutani MS**, Klapman JB, Tuli R, El-Haddad G, Hoffs S, Wong FCL, Chasen B, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MHG, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. *Endosc Ultrasound* 2020; **9**: 24-30 [PMID: [31670288](#) DOI: [10.4103/eus.eus\\_44\\_19](#)]
- 3 **Zeng H**, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N, Han R, Liu S, Mu H, He Y, Xu Y, Fu Z, Zhou Y, Jiang J, Yang Y, Chen J, Wei K, Fan D, Wang J, Fu F, Zhao D, Song G, Jiang C, Zhou X, Gu X, Jin F, Li Q, Li Y, Wu T, Yan C, Dong J, Hua Z, Baade P, Bray F, Jemal A, Yu XQ, He J. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. *Lancet Glob Health* 2018; **6**: e555-e567 [PMID: [29653628](#) DOI: [10.1016/S2214-109X\(18\)30127-X](#)]
- 4 **Zhao C**, Gao F, Li Q, Liu Q, Lin X. The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China. *Pancreas* 2019; **48**: 309-314 [PMID: [30855427](#) DOI: [10.1097/MPA.0000000000001222](#)]
- 5 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: [30207593](#) DOI: [10.3322/caac.21492](#)]
- 6 **Rahib L**, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; **74**: 2913-2921 [PMID: [24840647](#) DOI: [10.1158/0008-5472.CAN-14-0155](#)]
- 7 **Esposito I**, Konukiewicz B, Schlitter AM, Klöppel G. Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. *World J Gastroenterol* 2014; **20**: 13833-13841 [PMID: [25320520](#) DOI: [10.3748/wjg.v20.i38.13833](#)]
- 8 **Arya N**, Wyse JM, Jayaraman S, Ball CG, Lam E, Paquin SC, Lightfoot P, Sahai AV. A proposal for the ideal algorithm for the diagnosis, staging, and treatment of pancreas masses suspicious for pancreatic adenocarcinoma: Results of a working group of the Canadian Society for Endoscopic Ultrasound. *Endosc Ultrasound* 2020; **9**: 154-161 [PMID: [32584310](#)]
- 9 **Costache MI**, Cazacu IM, Dietrich CF, Petrone MC, Arcidiacono PG, Giovannini M, Bories E, Garcia JI, Siyu S, Santo E, Popescu CF, Constantin A, Bhutani MS, Săftoiu A. Clinical impact of strain histogram EUS elastography and contrast-enhanced EUS for the differential diagnosis of focal pancreatic masses: A prospective multicentric study. *Endosc Ultrasound* 2020; **9**: 116-121 [PMID: [32295969](#) DOI: [10.4103/eus.eus\\_69\\_19](#)]
- 10 **Ge N**, Brugge WR, Saxena P, Sahai A, Adler DG, Giovannini M, Pausawasdi N, Santo E, Mishra G, Tam W, Kida M, de la Mora-Levy JG, Sharma M, Umar M, Katanuma A, Lee L, Garg PK, Eloubeidi MA, Yu HK, Rajman I, Arturo Arias BL, Bhutani M, Carrara S, Rai P, Mukai S, Palazzo L, Dietrich CF, Nguyen NQ, El-Nady M, Poley JW, Guaraldi S, Kalaitzakis E, Sabbagh LC, Lariño-Noia J, Gress FG, Lee YT, Rana SS, Fusaroli P, Hocke M, Dhir V, Lakhtakia S, Ratanachu-Ek T, Chalaphathi Rao AS, Vilmann P, Okasha HH, Irisawa A, Ponnudurai R, Leong AT, Artifon E, Iglesias-Garcia J, Săftoiu A, Larghi A, Robles-Medrande C, Sun S. An international, multi-institution survey of the use of EUS in the diagnosis of pancreatic cystic lesions. *Endosc Ultrasound* 2019; **8**: 418-427 [PMID: [31552915](#) DOI: [10.4103/eus.eus\\_61\\_19](#)]
- 11 **Zeng S**, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. *Int J Mol Sci* 2019; **20** [PMID: [31514451](#) DOI: [10.3390/ijms20184504](#)]
- 12 **Cho DY**, Ko HM, Kim J, Kim BW, Yun YS, Park JI, Ganesan P, Lee JT, Choi DK. Scoparone Inhibits LPS-Simulated Inflammatory Response by Suppressing IRF3 and ERK in BV-2 Microglial Cells. *Molecules* 2016; **21** [PMID: [27983636](#) DOI: [10.3390/molecules21121718](#)]
- 13 **Liu B**, Deng X, Jiang Q, Li G, Zhang J, Zhang N, Xin S, Xu K. Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf2 axis and PI3K/AKT/mTOR pathway in macrophages. *Biomed Pharmacother* 2020; **125**: 109895 [PMID: [32000066](#) DOI: [10.1016/j.biopha.2020.109895](#)]
- 14 **Wang Y**, Wang M, Chen B, Shi J. Scoparone attenuates high glucose-induced extracellular matrix accumulation in rat mesangial cells. *Eur J Pharmacol* 2017; **815**: 376-380 [PMID: [28970015](#) DOI: [10.1016/j.ejphar.2017.09.039](#)]
- 15 **Xu M**, Cai J, Wei H, Zhou M, Xu P, Huang H, Peng W, Du F, Gong A, Zhang Y. Scoparone Protects Against Pancreatic Fibrosis via TGF-β/Smad Signaling in Rats. *Cell Physiol Biochem* 2016; **40**: 277-286 [PMID: [27855406](#) DOI: [10.1159/000452544](#)]
- 16 **Chen YL**, Huang HC, Weng YI, Yu YJ, Lee YT. Morphological evidence for the antiatherogenic effect of scoparone in hyperlipidaemic diabetic rabbits. *Cardiovasc Res* 1994; **28**: 1679-1685 [PMID: [7842462](#) DOI: [10.1093/cvr/28.11.1679](#)]

- 17 **Jung SH**, Lee GB, Ryu Y, Cui L, Lee HM, Kim J, Kim B, Won KJ. Inhibitory effects of scoparone from chestnut inner shell on platelet-derived growth factor-BB-induced vascular smooth muscle cell migration and vascular neointima hyperplasia. *J Sci Food Agric* 2019; **99**: 4397-4406 [PMID: 30861122 DOI: 10.1002/jsfa.9674]
- 18 **Park S**, Kim JK, Oh CJ, Choi SH, Jeon JH, Lee IK. Scoparone interferes with STAT3-induced proliferation of vascular smooth muscle cells. *Exp Mol Med* 2015; **47**: e145 [PMID: 25744297 DOI: 10.1038/emmm.2014.113]
- 19 **Jang SI**, Kim YJ, Kim HJ, Lee JC, Kim HY, Kim YC, Yun YG, Yu HH, You YO. Scoparone inhibits PMA-induced IL-8 and MCP-1 production through suppression of NF-kappaB activation in U937 cells. *Life Sci* 2006; **78**: 2937-2943 [PMID: 16376386 DOI: 10.1016/j.lfs.2005.11.020]
- 20 **Kielbus M**, Skalicka-Wozniak K, Grabarska A, Jeleniewicz W, Dmoszynska-Graniczka M, Marston A, Polberg K, Gawda P, Klatka J, Stepulak A. 7-substituted coumarins inhibit proliferation and migration of laryngeal cancer cells in vitro. *Anticancer Res* 2013; **33**: 4347-4356 [PMID: 24123002]
- 21 **Kim JK**, Kim JY, Kim HJ, Park KG, Harris RA, Cho WJ, Lee JT, Lee IK. Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity. *PLoS One* 2013; **8**: e80391 [PMID: 24260381 DOI: 10.1371/journal.pone.0080391]
- 22 **Gfeller D**, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Res* 2014; **42**: W32-W38 [PMID: 24792161 DOI: 10.1093/nar/gku293]
- 23 **Szklarczyk D**, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. *Nucleic Acids Res* 2016; **44**: D380-D384 [PMID: 26590256 DOI: 10.1093/nar/gkv1277]
- 24 **Stelzer G**, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI, Nudel R, Lieder I, Mazor Y, Kaplan S, Dahary D, Warshawsky D, Guan-Golan Y, Kohn A, Rappaport N, Safran M, Lancet D. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Curr Protoc Bioinformatics* 2016; **54**: 1.30.1-1.30.33 [PMID: 27322403 DOI: 10.1002/cpbi.5]
- 25 **Davis AP**, Grondin CJ, Johnson RJ, Sciaky D, Wieggers J, Wieggers TC, Mattingly CJ. Comparative Toxicogenomics Database (CTD): update 2021. *Nucleic Acids Res* 2021; **49**: D1138-D1143 [PMID: 33068428 DOI: 10.1093/nar/gkaa891]
- 26 **Liao Y**, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res* 2019; **47**: W199-W205 [PMID: 31114916 DOI: 10.1093/nar/gkz401]
- 27 **Kanehisa M**, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000; **28**: 27-30 [PMID: 10592173 DOI: 10.1093/nar/28.1.27]
- 28 **Szklarczyk D**, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019; **47**: D607-D613 [PMID: 30476243 DOI: 10.1093/nar/gky1131]
- 29 **Shannon P**, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003; **13**: 2498-2504 [PMID: 14597658 DOI: 10.1101/gr.1239303]
- 30 **Assenov Y**, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. *Bioinformatics* 2008; **24**: 282-284 [PMID: 18006545 DOI: 10.1093/bioinformatics/btm554]
- 31 **Chin CH**, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 2014; **8** Suppl 4: S11 [PMID: 25521941 DOI: 10.1186/1752-0509-8-S4-S11]
- 32 **Tang Z**, Li C, Kang B, Gao G, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* 2017; **45**: W98-W102 [PMID: 28407145 DOI: 10.1093/nar/gkx247]
- 33 **Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**: 402-408 [PMID: 11846609 DOI: 10.1006/meth.2001.1262]
- 34 **Shen B**. A New Golden Age of Natural Products Drug Discovery. *Cell* 2015; **163**: 1297-1300 [PMID: 26638061 DOI: 10.1016/j.cell.2015.11.031]
- 35 **Fresno Vara JA**, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. *Cancer Treat Rev* 2004; **30**: 193-204 [PMID: 15023437 DOI: 10.1016/j.ctrv.2003.07.007]
- 36 **Lee RS**, House CM, Cristiano BE, Hannan RD, Pearson RB, Hannan KM. Relative Expression Levels Rather Than Specific Activity Plays the Major Role in Determining In Vivo AKT Isoform Substrate Specificity. *Enzyme Res* 2011; **2011**: 720985 [PMID: 21869924 DOI: 10.4061/2011/720985]
- 37 **Zhang X**, Zhang S, Yamane H, Wahl R, Ali A, Lofgren JA, Kendall RL. Kinetic mechanism of AKT/PKB enzyme family. *J Biol Chem* 2006; **281**: 13949-13956 [PMID: 16540465 DOI: 10.1074/jbc.M601384200]
- 38 **Yang H**, Liu JX, Shang HX, Lin S, Zhao JY, Lin JM. Qingjie Fuzheng granules inhibit colorectal cancer cell growth by the PI3K/AKT and ERK pathways. *World J Gastrointest Oncol* 2019; **11**: 377-392 [PMID: 31139308 DOI: 10.4251/wjgo.v11.i5.377]
- 39 **Gu JF**, Fu W, Qian HX, Gu WX, Zong Y, Chen Q, Lu L. TBL1XR1 induces cell proliferation and

- inhibit cell apoptosis by the PI3K/AKT pathway in pancreatic ductal adenocarcinoma. *World J Gastroenterol* 2020; **26**: 3586-3602 [PMID: [32742128](#) DOI: [10.3748/wjg.v26.i25.3586](#)]
- 40 **Xu D**, Zhou Y, Xie X, He L, Ding J, Pang S, Shen B, Zhou C. Inhibitory effects of canagliflozin on pancreatic cancer are mediated *via* the downregulation of glucose transporter1 and lactate dehydrogenase A. *Int J Oncol* 2020; **57**: 1223-1233 [PMID: [32901837](#) DOI: [10.3892/ijo.2020.5120](#)]





Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

